Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Promethazine Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Frequen-ZZZ SleepPad Investigational Device POC

NCT05908344
View directory record Official record
Conditions
Insomnia, Sleep, Sleep Disturbance
Interventions
Activated Sleep Pad system (Frequen-ZZZ), Deactivated Sleep Pad system (Frequen-ZZZ)
Device
Lead sponsor
Kunasan Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

NCT00051909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY451395
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
9
States / cities
Beverly Hills, California • Fresno, California • Boca Raton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil

NCT00991809
View directory record Official record
Conditions
Hyperalgesia
Interventions
Alfentanil, Diphenhydramine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

NCT01683084
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Telmisartan, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
50 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Phase 1 Interventional

Tazemetostat and Palbociclib With CPX-351for R/R AML

NCT05627232
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Palbociclib
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

NCT00381134
View directory record Official record
Conditions
Diabetes, Kidney Disease, Hypertension
Interventions
losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Metoclopramide for Migraine: A Dose Finding Study

NCT00682734
View directory record Official record
Conditions
Migraine
Interventions
metoclopramide, Diphenhydramine 25mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"

NCT03081416
View directory record Official record
Conditions
Headache, Intranasal Ketamine
Interventions
Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 20, 2026, 10:12 PM EDT
Not listed Not applicable Interventional

Auricular Acupuncture vs SOC in Migraine HA

NCT02681211
View directory record Official record
Conditions
Migraine Headache
Interventions
Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL
Other · Drug
Lead sponsor
University of Louisville
Other
Eligibility
8 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

NCT00562809
View directory record Official record
Conditions
Hypertension
Interventions
IRBESARTAN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 20, 2026, 10:12 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

NCT02386293
View directory record Official record
Conditions
Hypertension, Obesity, Stress, Psychological, Blood Pressure
Interventions
Irbesartan, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Enrolling by invitation Phase 3 Interventional

Reduce Opiate Exposure With ACL Surgery

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease
Interventions
Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Results available

Study of Open Label Losartan in COVID-19

NCT04335123
View directory record Official record
Conditions
COVID-19
Interventions
Losartan
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

TPI 287 in Breast Cancer Metastatic to the Brain

NCT01332630
View directory record Official record
Conditions
Breast Cancer
Interventions
TPI 287, Dexamethasone, Benadryl, Ranitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Losartan in the Treatment of NAFLD in Children

NCT01913470
View directory record Official record
Conditions
NAFLD
Interventions
Losartan
Drug
Lead sponsor
Miriam Vos, MD
Other
Eligibility
11 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional

The Effect of White and Pink Noise on Hospitalized Older Adults

NCT03485183
View directory record Official record
Conditions
Delirium in Old Age
Interventions
White/Pink Noise, Control Group
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Early Phase 1 Interventional

N-of-1 Trials for Blood Pressure Medications in Adults

NCT02744456
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
Losartan, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 20, 2026, 10:12 PM EDT